Wednesday, October 14, 2026

Strategy Hikes STRC Dividend to 12%, Authorizes $2B Buyback as mNAV Falls Below 1

Strategy overhauled its capital framework after its market-to-net-asset-value premium dropped below 1, signaling investors no longer trust its leveraged Bitcoin-accumulation model. The company raised its STRC preferred dividend to 12%, authorized a $2 billion buyback, and launched a monetization program, while Bitcoin ETFs shed $4 billion in a month.

LM Salvado
LM Salvado

July 16, 2026

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Strategy Hikes STRC Dividend to 12%, Authorizes $2B Buyback as mNAV Falls Below 1
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Strategy's market-to-net-asset-value (mNAV) premium has fallen below 1, the clearest signal yet that investors are pulling back from its leveraged Bitcoin-accumulation model. The company is now restructuring its capital framework in response.

Strategy raised its STRC preferred dividend to 12% to retain capital and hold investors amid the mNAV slide. It also authorized a $2 billion share buyback and launched a monetization program, moving beyond a strategy built solely on accumulating Bitcoin.

Michael Saylor, the company's chairman, sold a small amount of Bitcoin as part of the shift. Bitcoin ETFs recorded $4 billion in outflows over the same month, pointing to a broader cooling in institutional crypto demand beyond Strategy alone.

Regulators are moving in parallel. The Bank for International Settlements' annual report cast doubt on stablecoins' status as money, arguing they function more like exchange-traded fund shares than a means of payment.1 The BIS said stablecoins "trade off par" and show "redemption frictions... which we've literally never seen," and that they "don't settle on central bank balance sheets and can't guarantee par across issuers."1

The BIS also warned that dollar-denominated stablecoins are accelerating dollarization in fragile economies, weakening local currencies and undermining capital controls. "You can't enforce border rules on a self-custodied token," the institution said.1

The timing links two threads in crypto-adjacent finance: corporate Bitcoin treasuries built on leverage and premium valuation are showing their first real strain, while global regulators signal tighter scrutiny of the stablecoin infrastructure underpinning much of the crypto market. For Strategy, the capital framework overhaul marks a departure from its identity as a pure Bitcoin-accumulation vehicle toward one that also manages shareholder returns directly through dividends and buybacks.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· June 29, 2026
    Saylor's Strategy changes playbook and can now sell its bitcoin

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com